Fangshu Liu
Overview
Explore the profile of Fangshu Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
21
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun X, Li Y, Du J, Liu F, Wu C, Xiao W, et al.
Nat Commun
. 2025 Feb;
16(1):1358.
PMID: 39905002
Sphingolipid, ceramide for example, plays an essential role in regulating cancer cell death. Defects in the generation and metabolism of ceramide in cancer cells contribute to tumor cell survival and...
2.
Liu F, Sun X, Deng S, Wu Y, Liu X, Wu C, et al.
Stem Cell Res Ther
. 2024 Aug;
15(1):248.
PMID: 39113086
Background: The function of hematopoietic stem cells (HSC) is regulated by HSC internal signaling pathways and their microenvironment. Chemokines and chemokine ligands play important roles in the regulation of HSC...
3.
Jiang X, Huang K, Sun X, Li Y, Hua L, Liu F, et al.
iScience
. 2024 Jan;
27(1):108691.
PMID: 38205254
Tumors maintain an alkaline intracellular environment to enable rapid growth. The proton exporter NHE1 participates in maintenance of this pH gradient. However, whether targeting NHE1 could inhibit the growth of...
4.
Sun X, Du J, Meng H, Liu F, Yang N, Deng S, et al.
Cell Biol Toxicol
. 2023 Sep;
39(6):3255-3267.
PMID: 37768392
Anthracycline antitumor agents, such as doxorubicin (DOX), are effective in the treatment of solid tumors and hematological malignancies, but anthracycline-induced cardiotoxicity (AIC) limits their application as chemotherapeutics. Dexrazoxane (DEX) has...
5.
Hua L, Yang N, Li Y, Huang K, Jiang X, Liu F, et al.
Br J Haematol
. 2023 Jul;
202(5):971-984.
PMID: 37409755
Venetoclax inhibits acute myeloid leukaemia by inhibiting BCL-2 targeting, and a combination regimen with venetoclax has been explored. Although these regimens produce better clinical results, the vast majority of patients...
6.
Liu F, Meng L, Wang H, Du C, Zhu J, Xiong Q, et al.
J Biomater Sci Polym Ed
. 2023 Jun;
34(16):2179-2197.
PMID: 37369107
A novel redox-responsive mPEG-SS-PLA (PSP) polymeric micelle was synthesized and prepared for the delivery of sorafenib (SAF) and curcumin (CUR). And a series of validations were conducted to confirm the...
7.
Meng L, Liu F, Du C, Zhu J, Xiong Q, Li J, et al.
Molecules
. 2023 May;
28(9).
PMID: 37175234
In this work, glucose transporter-1 (GLUT-1) and glutathione (GSH) over-expression in liver cancer was utilized to design a reduction-responsive and active targeting drug delivery system AG-PEG-SS-PCL (APSP) for the delivery...
8.
Deng S, Du J, Gale R, Wang L, Zhan H, Liu F, et al.
Leukemia
. 2023 Apr;
37(7):1407-1412.
PMID: 37120691
Acute myeloid leukaemia (AML) cells metabolise glucose by glycolysis-based re-programming. However, how glucose uptake is partitioned between leukaemia cells and other cells of the bone marrow micro-environment is unstudied. We...
9.
Sun X, Meng H, Xiao J, Liu F, Du J, Zeng H
Toxicology
. 2023 Apr;
490:153512.
PMID: 37062353
Anthracycline antineoplastics are effective in the treatment of hematological malignancies and solid tumors. However, the anthracycline-induced cardiotoxicity (AIC) limits their use as chemotherapeutic agents. Autophagy-based therapies have been explored to...
10.
Liu F, Deng S, Li Y, Du J, Zeng H
Front Genet
. 2023 Jan;
13:1081262.
PMID: 36685828
Acute myeloid leukemia (AML) is a heterogeneous malignant disease. , the gene encoding mitochondrial carrier subfamily of solute carrier proteins, was reported to be overexpressed in certain solid tumors. However,...